NovaBridge Biosciences names Chuck Silberstein CFO

NBP•2026-10-28

NovaBridge Biosciences appointed Chuck Silberstein as chief financial officer, effective November 2, 2026. He succeeds Kyler Lei and previously led FytonBio and served as CFO of GentiBio and Applied Therapeutics.

1. CFO appointment

NovaBridge Biosciences appointed Chuck Silberstein as chief financial officer, effective November 2, 2026. He succeeds Kyler Lei, who is stepping down. Silberstein was co-founder and CEO of FytonBio and also served as CFO of GentiBio and Applied Therapeutics.

NovaBridge Biosciences names Chuck Silberstein CFO

1. CFO appointment

Related News

Palvella announces FDA acceptance and priority review of Qtorin rapamycin NDA; February 28, 2027 PDUFA target date set

Digi Power X publishes update to financial calendar

Wingstop sees FY2026 domestic same-store sales decline of about 6.5% to 7%

Hope Bancorp declares quarterly cash dividend of $0.14 per share

Frequency Electronics announces approximately $12 million in new contract awards supporting space and defense programs